18F-FDG PET/CT在非小细胞肺癌免疫治疗疗效和预后评估中的研究进展  

Advances of~(18)F-FDG PET/CT in Immunotherapy Response Assessment and Outcome Prediction for Non-Small Cell Lung Cancer Patients

作　　者：张倩 陶秀丽 吴宁 ZHANG Qian;TAO Xiuli;WU Ning(National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China)

机构地区：[1]国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院,北京100021

出　　处：《中国肿瘤》2024年第3期247-253,共7页China Cancer

基　　金：国家自然科学基金青年科学基金项目(82001870)。

摘　　要：免疫治疗显著改善了晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的生存,但至今仍缺乏有效的生物标志物预测免疫治疗的疗效和预后。18-氟-2-脱氧-D-葡萄糖(18-fluoro-2-deoxy-D-glucose,^(18)F-FDG)PET/CT作为一种无创的功能成像,能够表征全身肿瘤的糖代谢水平,在肿瘤免疫治疗的临床应用中展现出巨大潜力。全文就^(18)F-FDG PET/CT在NSCLC免疫治疗疗效和预后评估中的研究进展进行综述。Immunotherapy has significantly improved the survival of patients with advanced nonsmall cell lung cancer(NSCLC).However,there have not been reliable biomarkers to assess the efficacy and predict the outcome of immunotherapy.As a non-invasive functional imaging,18-fluoro-2-deoxy-D-glucose(^(18)F-FDG)PET/CT reflects glucose metabolism of tumors throughout the body,and has shown potential in clinical applications of immunotherapy.This paper reviews the progress of ^(18)F-FDG PET/CT in immunotherapy efficacy assessment and outcome prediction for NSCLC patients.

关 键 词：非小细胞肺癌 18F-FDG 正电子发射断层显像术 体层摄影术 X射线计算机 免疫治疗 

分 类 号：R734.2[医药卫生—肿瘤]